Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") is pleased to announce that following an application to The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Stock Exchange has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules (the "**Relevant Rules**") to the Company.

As a result of the dis-application of the Relevant Rules, the "B" marker will no longer be affixed to the Company's English and Chinese short name from April 14, 2026. The Company's shares will be traded on the Stock Exchange under the new stock short name of "SKB BIO" in English and "科倫博泰生物" in Chinese. The stock code of the Company remains unchanged as "6990".

REASONS FOR THE DIS-APPLICATION OF THE RELEVANT RULES

The Company is a biopharmaceutical company principally engaged in the research and development, manufacturing and commercialization of novel drugs. The Company listed its H shares on the Main Board of the Stock Exchange on July 11, 2023 pursuant to Chapter 18A of the Listing Rules.

The Company now satisfies the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules. In particular, the Company has a trading record of at least three financial years, management continuity for at least the three preceding financial years and ownership continuity and control for at least the most recent audited financial year. The Company's market capitalization as of April 8, 2026 was approximately HKD113.6 billion, which is in excess of HKD4.0 billion as required under Rule 8.05(3) of the Listing Rules. As stated in the

annual results announcement of the Company for the year ended December 31, 2025 published on March 23, 2026, the Company's total revenue for the year ended December 31, 2025, being the most recent audited financial year, was approximately RMB2,057.9 million, among which, revenue from sales of pharmaceutical products developed by the Company amounted to RMB542.7 million (equivalent to approximately HKD619.2 million). Therefore, the Company has been generating a revenue of more than HKD500.0 million for the most recent audited financial year as required under Rule 8.05(3) of the Listing Rules. Accordingly, the Company qualifies for listing under Rule 8.05(3) of the Listing Rules and the Stock Exchange has therefore granted its approval for the application for dis-application of the Relevant Rules to the Company.

EFFECTS OF THE DIS-APPLICATION OF THE RELEVANT RULES

Following the dis-application of the Relevant Rules, the "B" marker will cease to be affixed to the Company's English and Chinese stock short name. There will be otherwise no effect on the existing share certificates in respect of the Company's Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates for holders of the Company's Shares. No other changes will be made to the English or Chinese stock short name of the Company, the existing share certificates, the board lot size, the trading currency of the Company's Shares and the share registrar and transfer offices of the Company following the dis-application of the Relevant Rules.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, April 9, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.

For the purpose of this announcement and for illustrative purpose only, conversions of RMB to HKD are based on the exchange rate of RMB0.87651=HKD1.00. No representation is made that any amounts in HKD or RMB can be or could have been converted at the relevant dates at the above rate, at any other rates, or at all.